Sanctuary Advisors LLC Raises Stock Holdings in Kenvue Inc. (NYSE:KVUE)

Sanctuary Advisors LLC lifted its holdings in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 166.3% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 544,890 shares of the company's stock after purchasing an additional 340,266 shares during the period. Sanctuary Advisors LLC's holdings in Kenvue were worth $13,121,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently modified their holdings of KVUE. Boyar Asset Management Inc. raised its position in Kenvue by 7.2% during the 3rd quarter. Boyar Asset Management Inc. now owns 29,171 shares of the company's stock valued at $675,000 after purchasing an additional 1,948 shares during the last quarter. Bard Financial Services Inc. boosted its stake in shares of Kenvue by 5.7% during the 3rd quarter. Bard Financial Services Inc. now owns 106,790 shares of the company's stock valued at $2,470,000 after purchasing an additional 5,750 shares in the last quarter. Soltis Investment Advisors LLC grew its holdings in shares of Kenvue by 3.7% during the 3rd quarter. Soltis Investment Advisors LLC now owns 151,858 shares of the company's stock worth $3,512,000 after acquiring an additional 5,475 shares during the period. TD Private Client Wealth LLC lifted its position in Kenvue by 5.6% during the third quarter. TD Private Client Wealth LLC now owns 129,127 shares of the company's stock valued at $2,987,000 after buying an additional 6,901 shares during the period. Finally, Sunbelt Securities Inc. boosted its stake in Kenvue by 3.1% during the third quarter. Sunbelt Securities Inc. now owns 29,671 shares of the company's stock worth $686,000 after acquiring an additional 905 shares in the last quarter. Institutional investors own 97.64% of the company's stock.

Kenvue Price Performance

Shares of KVUE stock traded down $0.11 on Friday, hitting $22.21. 9,184,286 shares of the stock traded hands, compared to its average volume of 17,639,725. The firm has a market cap of $42.58 billion, a price-to-earnings ratio of 40.38, a PEG ratio of 2.02 and a beta of 1.36. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The firm has a 50 day simple moving average of $22.95 and a two-hundred day simple moving average of $21.17. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $24.46.

Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.27 by $0.01. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The business had revenue of $3.90 billion for the quarter, compared to the consensus estimate of $3.92 billion. During the same period in the previous year, the business earned $0.31 earnings per share. The business's revenue was down .4% on a year-over-year basis. As a group, equities research analysts predict that Kenvue Inc. will post 1.07 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, November 27th. Stockholders of record on Wednesday, November 13th were given a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a dividend yield of 3.69%. The ex-dividend date was Wednesday, November 13th. Kenvue's payout ratio is currently 149.09%.

Analysts Set New Price Targets

KVUE has been the topic of several analyst reports. JPMorgan Chase & Co. boosted their target price on Kenvue from $24.00 to $25.00 and gave the stock an "overweight" rating in a report on Friday, October 11th. Royal Bank of Canada raised Kenvue from a "hold" rating to a "moderate buy" rating in a research report on Monday, December 9th. Jefferies Financial Group initiated coverage on Kenvue in a research report on Tuesday, September 24th. They issued a "buy" rating and a $27.00 target price for the company. Piper Sandler raised their price target on shares of Kenvue from $20.00 to $21.00 and gave the company a "neutral" rating in a report on Monday, September 23rd. Finally, Barclays upgraded shares of Kenvue to a "hold" rating in a report on Thursday. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $22.64.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.